Given that HFpEF is a heterogeneous disease, it is unlikely to react to a one-size fits all treatment. We are focusing on different patient characteristics, including specific etiology of HFpEF (advanced aged, hypertensive, cardiometabolic or renal injury) coupled to circulating biomarkers of inflammation in the aim to identify discrete phenogroups of HFpEF. The aim is to create an understanding of what phenogroup is most likely to benefit from specific anti-inflammatory treatments to be developed in our project.
In addition, by advancing our knowledge of the potential prognosis of different HFpEF phenogroups, we hope to contribute crucial clinical information on treatment targets adapted to each patient.
This approach is called Personalized Medicine – and it means: the right treatment for the right patient”.
A DIVA should expect nothing less. Be a HFpEF-DIVA!